<DOC>
	<DOC>NCT02456740</DOC>
	<brief_summary>Randomized, stratified, double-blind, placebo-controlled, parallel-group, multi-center study followed by active-treatment phase. To evaluate the effect of AMG 334 compared to placebo on the change from baseline in monthly migraine days.</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention</brief_title>
	<detailed_description>Randomized, stratified, double-blind, placebo-controlled, parallel-group, multi-center study followed by active-treatment phase. Adults with one-year history of episodic migraine and currently, previously or never received migraine prophylactic medication will be randomized to one of two AMG 334 treatment groups or a placebo treatment group during the double blind treatment phase. During the active treatment phase, subjects will be randomized to one of the two AMG 334 treatment groups.</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>History of migraine (with or without aura) for ≥ 12 months prior to screening according to the IHS Classification ICHD3 (Headache Classification Committee of the International Headache Society, 2013) Migraine frequency: ≥ 4 and &lt; 15 migraine days per month on average across the 3 months prior to screening and during baseline Headache frequency: &lt; 15 headache days per month on average across the 3 months prior to screening and baseline Demonstrated at least 80% compliance with the eDiary. Older than 50 years of age at migraine onset History of cluster headache or hemiplegic migraine headache Unable to differentiate migraine from other headache No therapeutic response with &gt; 2 medication categories for prophylactic treatment of migraine after an adequate therapeutic trial Used a prohibited medication, device, or procedure within 2 months prior to the start of the baseline phase or during the baseline phase Concomitant use of 2 or more medications with possible migraine prophylactic effects within 2 months prior to the start of the baseline phase or during the baseline phase. If only 1 prophylactic medication is used, the dose must be stable within 2 months prior to the start of the baseline phase and throughout the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Headache</keyword>
	<keyword>Prevention</keyword>
	<keyword>Prophylaxis</keyword>
</DOC>